Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled Phase 2 study of fenebrutinib in relapsing multiple sclerosis
2021-003772-14Phase 2Active
- Sponsor
- Roche
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in multiple sclerosis (MS) comparing Fenebrutinib with Placebo (2 arms). Primary endpoint: Total number of new gadolinium-enhancing T1 lesions. Started Aug 2021; status: active.
02
Drugs
fenebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on 2021-003772-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-003772-14.